Cargando…
Metastatic Urothelial Carcinoma from Transplanted Kidney with Complete Response to an Immune Checkpoint Inhibitor
BACKGROUND: Donor-derived malignancy is a rare complication in patients who undergo organ transplant. Approaches to treatment have largely been individualized based on clinical circumstances given the lack of evidence-based guidelines, with therapeutic options ranging from discontinuation of immunos...
Autores principales: | Chiang, Ryan S., Connor, Ashton A., Inman, Brant A., Foo, Wen-Chi, Howell, David N., Madden, John F., Ellis, Matthew J., Rege, Aparna S., Harrison, Michael R. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7773455/ https://www.ncbi.nlm.nih.gov/pubmed/33425425 http://dx.doi.org/10.1155/2020/8881841 |
Ejemplares similares
-
Vinflunine for the treatment of advanced or metastatic transitional cell carcinoma of the urothelial tract: an evidence-based review of safety, efficacy, and place in therapy
por: Brousell, Steven C, et al.
Publicado: (2018) -
PD-L1/PD-1 Biomarker for Metastatic Urothelial Cancer that Progress Post-platinum Therapy: A Systematic Review and Meta-analysis
por: Tan, Wei Phin, et al.
Publicado: (2019) -
Biomarkers of the Response to Immune Checkpoint Inhibitors in Metastatic Urothelial Carcinoma
por: Chen, Siteng, et al.
Publicado: (2020) -
Metastatic urothelial carcinoma to the liver with unknown primary tumor
por: Cheung, Carling, et al.
Publicado: (2019) -
Outlook into the future of front-line immune checkpoint inhibition in metastatic urothelial carcinoma
por: Brown, Jason R., et al.
Publicado: (2021)